Current Treatment Options in Oncology最新文献_第7页

Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers. 妇科癌症幸存者激素替代疗法的最新进展。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-01 Epub Date: 2025-03-05 DOI: 10.1007/s11864-025-01298-5

Megan Gorman, Karin Shih

{"title":"Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers.","authors":"Megan Gorman, Karin Shih","doi":"10.1007/s11864-025-01298-5","DOIUrl":"10.1007/s11864-025-01298-5","url":null,"abstract":"Opinion statement: Symptoms of menopause and the sequelae of gynecologic cancer treatment can be severe in their physical and mental impact on patient quality of life. Survivors of certain gynecologic cancers - namely, early-stage, low-grade endometrial cancers; epithelial and germ cell ovarian cancers; and early-stage squamous cell cervical, vulvar, and vaginal cancers - as well as those who have undergone risk-reducing surgery for BRCA or Lynch syndrome mutations may safely use hormone replacement therapy (HRT). Treatment is ideally initiated in patients younger than age 60 or within ten years of menopause. The decision to start treatment should be made on an individualized basis after discussion of risks, benefits, and symptom severity with patients. Data suggest that the safest HRT regimens in this population include low-dose vaginal estrogen for the treatment of vulvovaginal symptoms, or low-dose systemic estrogen for the treatment of vasomotor symptoms, combined with progesterone in patients with an intact uterus. Therapies such as SSRIs/SNRIs, vaginal moisturizers, pelvic floor physical therapy, and psychosocial counseling should also be considered when appropriate for their effectiveness in managing menopausal symptoms without the potential risk of hormones.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"179-186"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy. 通过VEGF/VEGFR抑制剂和免疫治疗增强结直肠癌的治疗。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-03-01 Epub Date: 2025-03-06 DOI: 10.1007/s11864-025-01306-8

Jing Jiao, You Wu, Shaoxian Wu, Jingting Jiang

{"title":"Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy.","authors":"Jing Jiao, You Wu, Shaoxian Wu, Jingting Jiang","doi":"10.1007/s11864-025-01306-8","DOIUrl":"10.1007/s11864-025-01306-8","url":null,"abstract":"Opinion statement: Colorectal cancer, ranking as the third most prevalent malignancy globally, substantially benefits from both immunotherapy and VEGF/VEGFR inhibitors. Nevertheless, the use of monotherapy proves inadequate in effectively tackling the heterogeneity of tumors and the intricacies of their microenvironment, frequently leading to drug resistance and immune evasion. This situation underscores the pressing need for innovative strategies aimed at augmenting the effectiveness and durability of treatments. Clinical research demonstrates that the combination of VEGF/VEGFR inhibitors (primarily including VEGF/VEGFR-targeted drugs and multi-kinase inhibitors) with immune checkpoint inhibitors creates a synergistic effect in the treatment of colorectal cancer. Our analysis explores how VEGF/VEGFR inhibitors recalibrate the tumor microenvironment, modulate immune cell functions, and influence the expression of immune checkpoints and cytokines. Furthermore, we critically evaluate the preclinical and clinical feasibility of these combined therapeutic approaches. Despite the potential for toxicity, the significant benefits and prospective applications of these strategies warrant thorough exploration. Exploring the synergistic mechanisms of these combined treatments has the potential to inaugurate a new paradigm in oncology, enabling more personalized and efficacious treatment modalities. Additionally, the synergy between VEGF/VEGFR inhibitors and nascent immunotherapies emerges as a promising field of inquiry.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"213-225"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy. 修正：双重和三重治疗时代的转移性激素敏感前列腺癌。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 DOI: 10.1007/s11864-025-01294-9

Anthony V Serritella, Maha Hussain

引用次数: 0

Advancements in Diagnosis and Treatment of Cardiac Sarcomas: A Comprehensive Review. 心脏肉瘤的诊断和治疗进展综述。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-31 DOI: 10.1007/s11864-024-01287-0

Xuezhe Wang, Xinchi Luan, Wenwen Yin, Yilin Wang, Xiaoxuan Li, Ruolan Chen, Guoliang Zhang, Ruizhe Zhao, Xue Dong, Zhishang Zhang, Yuchen Fan, Zhaodong Li, Xianming Chu, Shuang Wang

{"title":"Advancements in Diagnosis and Treatment of Cardiac Sarcomas: A Comprehensive Review.","authors":"Xuezhe Wang, Xinchi Luan, Wenwen Yin, Yilin Wang, Xiaoxuan Li, Ruolan Chen, Guoliang Zhang, Ruizhe Zhao, Xue Dong, Zhishang Zhang, Yuchen Fan, Zhaodong Li, Xianming Chu, Shuang Wang","doi":"10.1007/s11864-024-01287-0","DOIUrl":"10.1007/s11864-024-01287-0","url":null,"abstract":"Opinion statement: Cardiac sarcomas are rare, aggressive malignancies originating from various cardiac cell types, presenting significant challenges in both diagnosis and treatment. This comprehensive review explores recent advancements in diagnosis and treatment of cardiac angiosarcoma, fibrosarcoma, leiomyosarcoma, and rhabdomyosarcoma. And we briefly discuss the exceedingly rare occurrence of cardiac osteosarcoma and present our perspectives on its treatment. Development of these tumors is influenced by genetic mutations, environmental factors, and chromosomal abnormalities, necessitating a multidisciplinary approach for accurate diagnosis and management. Advanced imaging techniques, biomarkers, and immunohistochemical analysis assist in confirming the diagnosis and guiding treatment decisions. Surgical resection, adjuvant therapies, and personalized treatment strategies based on genetic profiling offer promising avenues for improving patient outcomes. Emerging therapeutic approaches, such as targeted therapies and immunotherapies, have shown promising progress in recent years. Despite these advancements, the prognosis for patient with cardiac sarcomas remains poor, highlighting the urgent need for continued research to refine treatment methods and enhance long-term survival outcomes. Ongoing efforts and clinical trials are essential for advancing the management of these rare and aggressive tumors, ultimately improving quality of life for affected patients.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"103-127"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma. 边缘区淋巴瘤的发病机制、诊断、治疗及预后研究进展。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 DOI: 10.1007/s11864-025-01293-w

Qingyang Zhang, Wenzhe Yan, Heng Li, Hongling Peng

{"title":"Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma.","authors":"Qingyang Zhang, Wenzhe Yan, Heng Li, Hongling Peng","doi":"10.1007/s11864-025-01293-w","DOIUrl":"10.1007/s11864-025-01293-w","url":null,"abstract":"Opinion statement: The management of marginal zone lymphoma (MZL), an indolent B-cell non-Hodgkin lymphoma, requires a personalized and adaptive approach due to its clinical and prognostic heterogeneity. We believe treatment should emphasize a balanced strategy considering the subtype, disease burden, symptoms, and actionable genetic or environmental factors, such as infections or autoimmune diseases. For asymptomatic patients with low tumor burden or disseminated disease, a watch-and-wait approach remains appropriate, given MZL's indolent nature and the risks of overtreatment. Conversely, for symptomatic or high-burden cases, early intervention with chemoimmunotherapy is recommended for effective disease control. Surgery remains essential for both diagnosis and the treatment of localized disease. Incorporating molecular profiling and prognostic models, such as MZL-IPI and POD24, is crucial for decision-making and risk stratification. Testing for infectious agents like Helicobacter pylori or Hepatitis C virus should be standard practice, as eradication therapy offers a targeted, less toxic, and effective option in select patients. With ongoing advancements in understanding dysregulated signaling pathways and the tumor microenvironment, we anticipate novel targeted therapies and combination regimens will further improve outcomes. We advocate for molecular testing at diagnosis to identify actionable biomarkers, particularly for patients with refractory or relapsed disease. Finally, MZL management requires vigilant follow-up with adjustments based on evolving disease features. Treatment decisions should integrate patient preferences, clinical context, and the latest evidence to maximize survival while preserving quality of life.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"142-155"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Review of Modified Intersphincteric Resection in the Treatment of Ultra-Low Rectal Cancer. 改良括约肌间切除术治疗超低位直肠癌的研究进展。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-23 DOI: 10.1007/s11864-025-01291-y

Danni Li, Xi Xiong, Pan Diao, Jitao Hu, Wenbo Niu, Guiying Wang, Baokun Li

引用次数: 0

Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer. 小细胞肺癌免疫治疗应答的候选生物标志物。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-22 DOI: 10.1007/s11864-025-01292-x

Yili Shen, Zhicong Liu, Yi Chen, Xuefei Shi, Shunli Dong, Bin Wang

{"title":"Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer.","authors":"Yili Shen, Zhicong Liu, Yi Chen, Xuefei Shi, Shunli Dong, Bin Wang","doi":"10.1007/s11864-025-01292-x","DOIUrl":"10.1007/s11864-025-01292-x","url":null,"abstract":"Opinion statement: Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immunotherapy to platinum-based chemotherapy offers sustained overall survival benefits and become the standard for the first-line setting of extensive-stage small-cell lung cancer. However, only a limited number of patients derive prolonged benefits. Although novel immunomodulatory agents and combination strategies are currently under investigation, identifying patients who are likely to obtain clinical benefits from this therapeutic approach is urgently needed. The modest therapeutic response to immunotherapy can be explained by various mechanisms. Traditional biomarkers do not guide immunotherapeutic decision-making in small-cell lung cancer. Notably, recent progress in the understanding of the molecular typing of small-cell lung cancer based on multi-omics data might bring new sights. This review summarizes the potential biomarkers for small-cell lung cancer immunotherapy based on clinical trials and preclinical studies. Moreover, important constraints in identifying biomarkers for small-cell lung cancer treatment are discussed.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"73-83"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms. 胃肠神经内分泌肿瘤免疫治疗策略的发展

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-23 DOI: 10.1007/s11864-024-01283-4

Arielle Urman, Ian Schonman, Ana De Jesus-Acosta

{"title":"Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms.","authors":"Arielle Urman, Ian Schonman, Ana De Jesus-Acosta","doi":"10.1007/s11864-024-01283-4","DOIUrl":"10.1007/s11864-024-01283-4","url":null,"abstract":"Opinion statement: Treatment for neuroendocrine neoplasms (NENs) is tailored to the tumor's site of origin, grade, and differentiation. NENs are categorized into two main types: well-differentiated neuroendocrine tumors (NETs), which tend to grow more slowly and are less aggressive, and poorly differentiated neuroendocrine carcinomas (NECs), which are highly aggressive and harder to treat. Treatment options for NETs range from somatostatin analogues and mTOR inhibitors to peptide receptor radionuclide therapy (PRRT) with Lutetium-177 dotatate. In cases where the disease progresses more rapidly, cytotoxic chemotherapy may also be considered. In contrast, chemotherapy plays a central role in treating NECs, often following protocols similar to those used for small cell lung cancer. Exciting progress is being made in the development of new therapies for NENs. Inspired by the success of immunotherapy in other cancers, clinical trials have begun to explore its potential in NENs. Early findings suggest that immune checkpoint inhibitors (ICIs) may offer benefits, especially in patients with higher-grade NETs and NECs. However, because NENs have an immunologically \"cold\" tumor microenvironment-meaning they are less likely to trigger an immune response-new strategies are needed to boost ICI efficacy. To overcome this challenge, researchers are exploring innovative approaches, such as combining dual ICIs or pairing ICIs with other therapeutic agents to make the tumors more responsive to immune attack. Moreover, there is growing enthusiasm for cutting-edge therapies designed to enhance the immune system's ability to recognize and destroy cancer cells. These include bispecific T cell engagers, chimeric antigen receptor T cells, tumor-infiltrating lymphocytes, oncolytic viruses, and cancer vaccines. While their effectiveness in NENs is still being studied, these approaches hold considerable promise, offering new hope for patients with this challenging and complex cancer type.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"92-102"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143025508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements. 复发/难治性多发性骨髓瘤精准治疗的靶点选择：最新进展

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-02-01 Epub Date: 2025-01-31 DOI: 10.1007/s11864-025-01290-z

Zhen Wang, Yanqi Song, Honglei Guo, Yuting Yan, Lin Ma, Baoshan Liu

{"title":"Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements.","authors":"Zhen Wang, Yanqi Song, Honglei Guo, Yuting Yan, Lin Ma, Baoshan Liu","doi":"10.1007/s11864-025-01290-z","DOIUrl":"10.1007/s11864-025-01290-z","url":null,"abstract":"Opinion statement: According to the guidelines, the primary treatment for multiple myeloma is still based on drugs such as carfilzomib, lenalidomide, or daratumumab. However, patients with relapsed/refractory multiple myeloma (RRMM) may be insensitive or develop resistance to the above therapeutic medications. Thus, formulating standardized and rational treatment regimens for such patients remains an area for consideration. Multidrug combinations are available for the therapy of patients with relapsed/refractory multiple myeloma to improve their clinical outcome and prevent the occurrence of multidrug resistance. For instance, combination therapy with immunomodulators, proteasome inhibitors, and CD38 monoclonal antibodies. With the development of genomics and molecular diagnostic technologies, RRMM has entered the era of precision therapy. Targeted immunotherapeutic drugs such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor-T (CAR-T) cells have shown promising clinical response rates and favorable safety profiles in several clinical and experimental studies. These cutting-edge medicinal treatments may provide new hope for a cure for RRMM. However, the choice of treatment regimen still needs to adhere to the principle of individualization. Generally, we recommend treatment with drugs of a new generation or novel mechanism of action for patients with RRMM who are first relapsed, such as next-generation proteasome inhibitors, next-generation immunomodulators, and CD38-based monoclonal antibody regimens. For multiple relapsed RRMM, we recommend choosing a combination regimen or participating in relevant clinical trials. Additionally, monoclonal antibodies have become the standard of care for patients with RRMM. With the introduction of CAR-T therapy, ADCs, and bispecific antibodies, RRMM patients are expected to achieve deep remissions and long-term survival again.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"128-141"},"PeriodicalIF":3.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A fishnet between nasopharyngeal carcinoma and resistance: the competing endogenous RNA network. 鼻咽癌与耐药之间的渔网：竞争的内源性RNA网络。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2025-01-01 Epub Date: 2025-01-15 DOI: 10.1007/s11864-024-01284-3

Mingtai Li, Tongtong Mo, Zisha Yang, Yunhong Yao, Yan Wang, Yi Zhao

引用次数: 0